Research

Dynamic diversity of the tryptophan pathway in chlamydiae: reductive evolution and a novel operon for tryptophan recapture

Gary Xie*†, Carol A Bonner† and Roy A Jensen*‡

Addresses: *Department of Microbiology and Cell Science, Gainesville, FL 32611, USA. †BioScience Division, Los Alamos National Laboratory, Los Alamos, NM 87544, USA. ‡Department of Chemistry, City College of New York, New York, NY 10031, USA.

Correspondence: Roy A Jensen. E-mail: rjensen@ufl.edu

Abstract

Background: Complete genomic sequences of closely related organisms, such as the chlamydiae, afford the opportunity to assess significant strain differences against a background of many shared characteristics. The chlamydiae are ubiquitous intracellular parasites that are important pathogens of humans and other organisms. Tryptophan limitation caused by production of interferon-γ by the host and subsequent induction of indoleamine dioxygenase is a key aspect of the host-parasite interaction. It appears that the chlamydiae have learned to recognize tryptophan depletion as a signal for developmental remodeling. The consequent non-cultivable state of persistence can be increasingly equated to chronic disease conditions.

Results: The genes encoding enzymes of tryptophan biosynthesis were the focal point of this study. Chlamyphila psittaci was found to possess a compact operon containing PRPP synthase, kynureninase, and genes encoding all but the first step of tryptophan biosynthesis. All but one of the genes exhibited translational coupling. Other chlamydiae (Chlamydia trachomatis, C. muridarum and Chlamyphila pneumoniae) lack genes encoding PRPP synthase, kynureninase, and either lack tryptophan-pathway genes altogether or exhibit various stages of reductive loss. The origin of the genes comprising the trp operon does not seem to have been from lateral gene transfer.

Conclusions: The factors that accommodate the transition of different chlamydial species to the persistent (chronic) state of pathogenesis include marked differences in strategies deployed to obtain tryptophan from host resources. C. psittaci appears to have a novel mechanism for intercepting an early intermediate of tryptophan catabolism and recycling it back to tryptophan. In effect, a host-parasite metabolic mosaic has evolved for tryptophan recycling.

Background

Chlamydiae are obligate intracellular pathogens that infect a variety of host organisms and exhibit individual tissue tropisms within a host species. The availability of complete genomic sequences for different species has provided a contemporary impetus for research to uncover specific relationships of chlamydial genes with the disease process, an impetus that is particularly welcome because the fastidious growth requirements of the organism have made it relatively intractable to experimentation. A number of analyses dealing with the comparative genomics of the chlamydiae have appeared in the recent literature [1-3].
Chlamydiae all progress through a life cycle that is intimately tied to success as a pathogen. The host is invaded by elementary bodies (EBs), which represent the extracellular infectious stage. The newly established EBs develop into intracellular reticulate bodies (RBs) that replicate in anticipation of maturation to EBs, which then lyse the host cell and initiate a new round of pathogen proliferation. Aggressive progress through repetitions of this cycle characterizes the acute disease process. Distinct changes in cell size, chromatin organization, membrane characteristics and metabolic competence constitute endpoints of a reversible developmental profile. A third metabolic stage called persistence is increasingly recognized to attend the chronic disease process [4]. The persistent state can be induced in vitro in tissue culture in response to various environmental cues such as nutrient limitation, antibiotic treatment or presence of interferon-γ (IFN-γ) [5,6]. All of the latter may act to trigger persistence by eliciting a degree of metabolic starvation [7]. In fact, it has been shown [7] that even normal blood plasma concentrations of amino acids are sufficiently limiting to infected cell cultures to promote the persistent state. Cells present in the persistent state have been detected in vivo, for example, in the synovial membranes of patients with Chlamydia-associated reactive arthritis [8]. Chlamydial cells poised in this state of metabolic latency exist as viable but non-cultivable cells that are ‘abnormally’ enlarged and which exhibit distinctive morphological characteristics [4].

One of the most prominent host protective responses to chlamydial infections has been the production of the T-cell-derived pro-inflammatory cytokine IFN-γ. This cytokine induces a variety of biochemical changes in host metabolism, apparently designed to thwart the ability of intracellular parasites to gain access to host resources. Relative sensitivity to IFN-γ varies, with C. muridarum and C. psittaci being relatively resistant compared to C. pneumoniae and the various C. trachomatis serovars. The relative insensitivity in vivo of C. muridarum, compared to human strains of C. trachomatis, is supported by the results of Cotter et al. [9] and Perry et al. [10]. Conflicts in the literature about the sensitivities of C. trachomatis and C. muridarum isolates to IFN-γ-mediated inhibition have been attributed to strain variation [10]. A well documented effect of IFN-γ has been its ability to decrease the availability of L-tryptophan in host cells. (Other anti-chlamydial effects involve the inducible synthesis of nitric oxide and deprivation of iron [11].) Although effective L-tryptophan starvation may resolve an acute infection, a more modulated degree of starvation for L-tryptophan is thought to be intimately involved in the phenomenon of persistence [12]. Thus, tryptophan limitation is increasingly recognized as an important factor in a variety of chronic disease conditions. As initially shown by Byrne et al. [13,14] and confirmed by others [15,16], IFN-γ acts by inducing indoleamine 2,3-dioxygenase, a host enzyme that converts L-tryptophan to L-formylkynurenine. (This broad-specificity monomeric enzyme is different from the non-homologous tryptophan 2,3-dioxygenase in liver [17] and brain tissues [18].) In addition, IFN-γ is a potent inducer of host tryptophanyl-tRNA synthetase [19]. Thus, the host not only decreases the pool of tryptophan available to intracellular parasites, but the remaining tryptophan molecules tend to be increasingly sequestered by the elevated level of host tryptophanyl-tRNA synthetase.

The biological relationship of IFN-γ, indoleamine dioxygenase, tryptophan limitation and the persistent state of intracellular parasitism extends beyond chlamydial parasites, as illustrated by consideration of Toxoplasma gondii [20]. This unicellular protozoan is a eukaryotic intracellular parasite that is subject to tryptophan limitation by exactly the same host mechanism used against the chlamydiae. The result is a generally widespread and asymptomatic state of chronic infection. Even extracellular bacteria such as group B streptococci (tryptophan auxotrophs) are inhibited by the IFN-γ mechanism of tryptophan limitation [21]. In this context, it may be no accident that pathogens such as Enterococcus faecalis, Haemophilus ducreyi, Clostridium difficile and Cl. perfringens are conspicuous tryptophan auxotrophs that maintain full competence for phenylalanine and tyrosine biosynthesis. The broad biological impact of host tryptophan catabolism is further illustrated by the hypothesis that tryptophan catabolism localized in placental tissue provides a mechanism (suppression of lymphocyte proliferation [22]) to prevent immune rejection of the mammalian fetus [23]. An additional example of the far-reaching consequences of host tryptophan catabolism is illustrated by the potential for persistent immune activation to disrupt the balance between serotonin and kynurenine production from tryptophan, thus linking the immunological network and neuropsychiatric consequences of serotonin imbalance [24].

Results and discussion
Dynamic gene reorganization and gene flux within the chlamydial plasticity zones
Figure 1 shows the gene organization in C. psittaci of tryptophan-pathway genes (trp), the large toxin gene lifA, a perforin-family gene, and a conserved hypothetical gene that is specific to the C. pneumoniae/C. psittaci lineage. lifA, the trp genes, the perforin-encoding gene and a few other genes can be generally recognized as interspecies residents of a ‘plasticity zone’ located near the terminus of replication [2]. As Read et al. [2] pointed out, dynamic events of gene shuffling, gene insertion and gene loss are apparent within this plasticity zone. They discussed the lack of variation in GC content and the absence of evidence for gene transfer, as well as the variation of tryptophan-pathway genes.

Substantial variation is also striking with respect to lifA. C. psittaci possesses a single copy of lifA, C. muridarum has three paralog copies, C. trachomatis has a single pseudogene with frameshift mutations and C. pneumoniae lacks lifA.
Figure 1
The tryptophan-recapture operon of Chlamydia psittaci (Cps). Genes are color-coded as shown in the key. Arrows indicate the direction of transcription. The nomenclature for tryptophan-pathway genes is that elaborated by Xie et al. [30], whereby genes encoding the five enzymes are named in order of the pathway steps. The two subunits of the first and fifth steps are given additional lower-case identifiers, that is, trpAa/trpAb and trpEa and trpEb (for simplicity, the trp genes are labeled without the trp identifier). Nucleotide spacing between genes is shown; negative values indicate open reading frames that overlap (translational coupling). The membrane-attack complex/perforin family protein from the chlamydiae, which belongs to PFAM (alternative name: prsA) encoding PRPP synthase are located at the 3′ end of the C. psittaci trp operon (see Figure 1). These genes, together with trpB, trpD, trpC, trpE and trpEa, comprise a compact operon in which all but one gene overlaps its neighbor in the operon (translational coupling). A regulatory gene, the trpR repressor, precedes the tryptophan operon on the amino-terminal side. A second paralog of the tryptophan synthase β subunit (trpEb-2) is also present in an extra-operonic location several genes upstream of trpR. The possible functional significance of this paralog as serine deaminase has been discussed elsewhere [30].
Host-parasite metabolic mosaic for tryptophan cycling

A rationale for inclusion of kprS and kynU in the C. psittaci tryptophan operon can be visualized from an examination of Figure 2. The ability of C. psittaci to synthesize L-tryptophan requires an alternative source of anthranilate (other than chorismate) as C. psittaci lacks anthranilate synthase. Kynurenine, intercepted from the host stream of catabolism, would satisfy this requirement given the presence of KynU. PRPP input is required for the TrpB-catalyzed step, and thus it was necessary for C. psittaci to recruit PRPP synthase (kprS) to the operon. The import of ATP (substrate for PRPP synthase) from the host is also probably needed, and the presence of ATP translocases in chlamydial genomes has been documented [1-3]. Alternative sources of ATP, for example, utilization of PEP by pyruvate kinase, are not altogether ruled out [31]. Finally, serine import is required for the tryptophan synthase step as chlamydiae are not competent for serine biosynthesis.

Figure 2 illustrates the mammalian ‘kynurenine’ pathway of tryptophan catabolism, which is prominent in liver and kidney. The initial step is rate limiting and is catalyzed by either of two enzymes: indoleamine 2,3-dioxygenase or tryptophan 2,3-dioxygenase. The latter is the true catabolic entity, has narrow specificity for tryptophan, and is inducible.
in the presence of tryptophan, glucocorticoids and heme cofactor [17]. In contrast, indoleamine 2,3-dioxygenase has broad substrate specificity and is capable of depleting low-to-normal concentrations of tryptophan if induced by IFN-γ. The overall host metabolism of tryptophan shown in Figure 2 reflects a general potential that is not necessarily realized in all cell types. The ultimate catabolic process to generate acetyl-CoA is a feature of liver and kidney organ systems. 2-Amino-3-carboxymuconate semialdehyde can be considered to be a branchpoint metabolite that either enters committed catabolism to acetyl-CoA or that enters biosynthesis to NAD+/NADP+. In the central nervous system, a number of kynurenine-pathway metabolites are neuroactive and appear to be involved in inflammatory neurological diseases [32]. Quinolinate can cause excitotoxic neuronal death. Kynurenic acid, derived from kynurenine by transamination, can antagonize the effect of quinolinate. 3-Hydroxykynurenine and 3-hydroxyanthranilate have been shown to cause apoptotic or necrotic neuronal death in cell cultures [32]. In glioblastoma cells (and apparently in human fibroblasts) kynurenine is an endpoint of tryptophan catabolism [33]. In human macrophages kynurenine is further metabolized [34]. Indoleamine dioxygenase is a rate-limiting step of tryptophan catabolism, and other steps are not known to be induced by IFN-γ. 3-Hydroxykynurenine is a prominent metabolite in the eye lens (it absorbs UV radiation) and probably supports eye pigmentation in the iris/ciliary body [35]. Hence, in some host tissue types, kynurenine is a largely dead-end product of tryptophan catabolism, whereas it has a variety of metabolic fates in other tissues. In either case, kynurenine generally exhibits a conspicuous pool size [36]. Thus, although C. psittaci apparently cannot utilize chorismate (for which it has an intact biosynthetic pathway) as a precursor of L-tryptophan, it has the potential to synthesize its own supply of L-tryptophan from host-generated kynurenine, ATP and L-serine.

It is of interest that the conversion of kynurenine to anthranilate and the conversion of 3-hydroxykynurenine to 3-hydroxyanthranilate are similar hydrolytic reactions. The host enzyme catalyzing the latter reaction is, in fact, a kynureninase which is a homolog of the C. psittaci KynU. Kynureninases have been reported to possess a range of substrate specificities that vary between high specificity for kynurenine and very high specificity for 3-hydroxykynurenine. The kynureninase of rat and human liver has an order-of-magnitude preference for 3-hydroxykynurenine [37], in contrast to a microbial kynureninase that exhibits a very high preference for kynurenine [38]. It seems likely that the C. psittaci KynU is specific for kynurenine, whereas the mammalian host may possess isozymes of different substrate specificity in different tissues.

An intriguing possible layer of additional complexity involves a competitive relationship between indoleamine dioxygenase and nitric oxide (NO) synthase (type II isomorph), which are both induced by IFN-γ. In murine macrophages, induction of NO synthase requires at least one additional stimulus (such as bacterial lipopolysaccharide (LPS)) that acts synergistically with IFN-γ ([39] and references therein). Metabolite flow to NAD+/NADP+ is proportional to the input availability of tryptophan in murine macrophages [40]. Under conditions in which there is induction of both indoleamine dioxygenase and NO synthase, an interplay of potential cross-pathway inhibitions are set in motion as illustrated in Figure 2. Nitric oxide inhibits indoleamine dioxygenase [41]. On the other hand, 3-hydroxyanthranilate inhibits both the expression and activity of NO synthase [39]. Thus, small-molecule products of each pathway can be mutually inhibitory.

Consider a scenario where C. psittaci has parasitized a host niche where 3-hydroxyanthranilate is a prominent metabolite, as in human macrophages [42]. The withdrawal of kynurenine from this flow route might undermine the levels of 3-hydroxyanthranilate sufficiently to release the restraints on NO synthase. The consequent increase in nitric oxide production might then tend to limit the availability of kynurenine as a result of inhibition of indoleamine dioxygenase. Although this might at first seem an unfavorable outcome for the C. psittaci parasitism, a finite but minimal supply of kynurenine might satisfy the highly limited metabolic demands of the persistent state.

**Did the C. psittaci trp operon originate by lateral gene transfer?**

The tryptophan operon of C. psittaci is probably derived from ancestral chlamydial genomes before modern events of gene reduction occurred. However, as the present-day C. psittaci operon is unique among chlamydiae, it is also possible that trp genes were lost and then reacquired by lateral gene transfer (LGT). As this would have happened recently (after divergence of C. psittaci from other chlamydial lineages), one might then expect the genes to have GC contents different from that of the overall C. psittaci genome (42%). Table 1 shows that each operon gene, as well as trpR and trpEb-2, are within the range expected for C. psittaci. However, the GC content of the donor genome could have fortuitously been near that of C. psittaci. If so, one might expect that the top hits returned from a BLAST search of each C. psittaci operon gene would not include other chlamydial genes and would be dominated by one organism having an appropriate GC content. The results (Table 1) show that this expectation was not realized.

It is perhaps intriguing that when C. psittaci kynureninase (KynU) was used as a query sequence, the top hits returned from BLAST were the KynU orthologs from man and mouse. Accordingly, the codon usage for the KynU proteins of C. psittaci and Homo sapiens (left half of Figure 3) was compared with the genomic codon usage of the respective
organisms (right half of Figure 3). The codon usage for arginine, leucine, proline and valine is distinctive in a comparison of C. psittaci and H. sapiens. The profile of codon usage for these amino acids by C. psittaci KynU clearly matches the genomic codon-usage profile of C. psittaci, but not that of H. sapiens. Thus, there is no evidence for a recent LGT of kynU between C. psittaci and H. sapiens.

Deterioration of tryptophan-pathway genes in the chlamydiae

Chlamydial species have generally undergone reductive evolution that includes an inability to synthesize tryptophan from chorismate. That the process of reductive evolution is ongoing is suggested by the variability of remaining remnants and by indications that some of these remnants are pseudogenes. At one extreme, C. pneumoniae has lost all tryptophan-pathway genes; C. muridarum has only one remnant (trpC); and C. trachomatis has three remnants (trpC, trpEa and trpEb). It appears that C. psittaci alone assigns a functional role to tryptophan-pathway genes, but it is a kynurenine-to-tryptophan pathway rather than a chorismate-to-tryptophan pathway. Thus, even C. psittaci is dependent upon host resources (that is, kynurenine) for tryptophan.

Figure 4 shows a sequence comparison of TrpC from E. coli with those from chlamydial species. Critical residues can be assessed with guidance from X-ray crystallography data (see legend) and invariant residues seen in multiple alignments. Given the presumed lack of selection for function in C. trachomatis and C. muridarum, it would not be surprising to find evidence of unfavorable mutations. Indeed, the mutations H335 → S335 (E. coli numbering) and G385 → E385 in C. trachomatis and C. muridarum, but not in C. psittaci, probably reflect unfavorable catalytic alterations (see heavy up arrows in Figure 4). Two changes in C. psittaci, not present in the other two chlamydial species (V292 → T292 and S429 → T429) are conservative changes that are presumably tolerated.

TrpEa from C. trachomatis has clearly accumulated deleterious mutations in contrast to the C. psittaci TrpEa (Figure 5). Comparison of these sequences with that of the well studied TrpEa from Salmonella typhimurium shows C. trachomatis TrpEa (but not C. psittaci TrpEa) to have the following changes at critical residues (S. typhimurium numbering): G61 → N61, G211 → R211, F/L212 → R212, and G234 → K234. In addition, the intersubunit signaling residue G181 has been changed to A181 in C. trachomatis. C. trachomatis TrpEa has a four-residue deletion between R192 and K193 that is unique in our comprehensive alignment of TrpEa. Xie et al. [30] pointed out that the elongated branch of C. trachomatis TrpEa, but not of C. psittaci TrpEa, on an unrooted phylogenetic tree of the TrpEa family was consistent with a likely pseudogene status for the former. The rapid deterioration of TrpEa is, in fact, apparent from differences in TrpEa from various serovars of C. trachomatis [43]. Thus, serovar B lacks TrpEa altogether, serovars A and C express severely truncated TrpEa proteins, whereas serovars D and L2 express full-length TrpEa proteins (although undoubtedly inactive).

The β subunits of tryptophan synthase in C. psittaci (two copies, Figure 1) and C. trachomatis appear to have all important residues conserved (Figure 6). This includes conserved catalytic residues and residues that are important for establishing intersubunit and intrasubunit salt bridges needed for formation of the α-β complex of tryptophan synthase. It

Table 1

| Gene      | %GC | Organism* | % Identity | Organism* | % Identity |
|-----------|-----|-----------|------------|-----------|------------|
| trpR      | 37  | Chlamydia trachomatis (42) | 61         | Vibrio cholerae (48) | 37         |
| trpB      | 40  | Arabidopsis thaliana (54)  | 45         | Methanococcus jannaschii (31) | 39         |
| trpD      | 37  | Streptomyces coelicolor (72) | 43         | Mycobacterium leprae (58) | 41         |
| trpC      | 41  | Chlamydia trachomatis (42) | 47         | Chlamydia muridarum (42) | 46         |
| trpEb     | 42  | Chlamydia trachomatis (42) | 74         | Aquifex aeolicus (43) | 59         |
| trpEa     | 39  | Chlamydia trachomatis (42) | 44         | Xylella fastidiosa (54) | 40         |
| kynU      | 40  | Homo sapiens (53) | 40         | Mus musculus (53) | 39         |
| kprS      | 37  | Thermotoga maritima (46) | 41         | Campylobacter jejuni (31) | 41         |
| trpEb-2†  | 42  | Chlamydia trachomatis (42) | 69         | Pyrococcus kodakaraensis (55) | 56         |

*Organisms having proteins returning the top hits after a BLAST search using the indicated C. psittaci genes on the left as query sequences are shown. Overall genomic %GC is given in parentheses. †Extra-operonic paralog of trpEb (see Figure 1).
Figure 3
Comparison of codon usage (arginine, leucine, proline and valine) for kynU genes from C. psittaci and H. sapiens with the corresponding whole-genome codon usages.
appears that there has been rapid deterioration of TrpEa, but not of TrpEb. This might suggest that TrpEb is under positive selection for some functional role other than that of tryptophan synthase. When TrpEb is not complexed with TrpEa, it has substantial activity as serine deaminase. Therefore, present-day TrpEb may function in the chlamydiae as serine deaminase, as has been proposed by Xie et al. Present-day TrpEb should be functional and TrpEa should not be functional. Fehlner-Gardiner et al. [44] sequenced TrpEa and TrpEb from all human serovars of C. trachomatis. All of the genital serovars expressed TrpEa and TrpEb proteins, but only TrpEb had catalytic activity. Interestingly, the catalytic indole-utilizing activity of TrpEb required a full-length TrpEb. It appears that these TrpEa proteins, although lacking their own catalytic activity, are still functional in maintaining the TrpEb activity. Even though most of the ocular serovars also had a potentially functional TrpEb, none of them would presumably utilize indole in vivo because of the absence of a full-length TrpEb. The authors propose that other bacteria in the microenvironment of genital serovars might be a source of indole, a situation not expected in the microenvironment of ocular serovars. In short, the tissue tropism correlates with ability to convert indole to...
l-tryptophan in vivo. This seems a reasonable possibility, although it does not explain why most of the ocular serovars have maintained a TrpEb that seems to have resisted reductive evolutionary forces. It would be interesting to know whether the serine deaminase activity of C. trachomatis TrpEb (an activity other than indole utilization suggested in this paper) requires full-length TrpEα or not.

**Overview of tryptophan-pathway variability in chlamydiae**

Shaw et al. [43] have correlated the variability in the number of tryptophan-pathway enzymes present in chlamydiae (in particular, the α subunit of tryptophan synthase) with varied sensitivity to IFN-γ treatment [16] and ease of demonstrating the transition to persistence in vitro. C. trachomatis A, B and C readily develop persistent characteristics following IFN-γ treatment [45]. Tryptophan has been reported to be essential for growth of serovars A, B and C, but not for growth of C. psittaci or serovars D-K and L2 of C. trachomatis [45]. Thus, C. trachomatis serovars A-C, but not serovars D-K or L1-L3, have been described as ‘tryptophan auxotrophs’ [43]. Likewise, C. pneumoniae, but not C. psittaci, has been described as a tryptophan auxotroph. Morrison [46] has also discussed the possible relationship of genes present or absent for tryptophan biosynthesis and the differential sensitivities of chlamydiae to inhibitory effects of IFN-γ. Shaw et al. [43] imply that C. trachomatis D, L2 and C. psittaci are competent for tryptophan biosynthesis, unlike C. trachomatis A, B and C. pneumoniae. This correlates nicely with proneness to persistence and the more demonstrable nutritional requirement for tryptophan in the latter strains, but not the former. However, from the current database information available, it appears likely that all chlamydiae, even C. psittaci, are tryptophan auxotrophs. As the host itself is incapable of tryptophan biosynthesis, the host is not a credible source of any biosynthetic intermediates. It is also noteworthy that only C. psittaci has PRPP synthase, which is needed for provision of PRPP (TrpB step). Thus, there seems to be no basis for the conclusion [43] that variations in C. trachomatis serovar pathogenesis can be directly linked to differences in TrpEα, and it therefore seems that the latter differences are coincidental. Differences in vaccine acquisition of the host resources are unknown variables that might distinguish different strains [47]. In this context, it seems possible that variation...
### Table 2

#### Key to sequence identifiers

| Genes evaluated                  | Gene-product acronym | NCBI GI number* |
|-----------------------------------|----------------------|-----------------|
| *trpC*                            |                      |                 |
| *Escherichia coli*                | Eco TrpC             | 16129223        |
| *Chlamydia trachomatis D*         | Ctra TrpC            | 7227938         |
| *Chlamydia muridarum*             | Cmu TrpC             | 8163265         |
| *Chlamydophila psittaci*          | Cpsi TrpC            | N/A             |
| *Pseudomonas aeruginosa*          | Pae TrpC             | 15598309        |
| *Neisseria gonorrhoeae*           | Ngo TrpC             | N/A             |
| *Neisseria meningitidis*          | Nme TrpC             | 15793859        |
| *Nitrosomonas europaea*           | Neu TrpC             | N/A             |
| *Bordetella pertussis*            | Bpe TrpC             | N/A             |
| *Bordetella bronchiseptica*       | Bbr TrpC             | N/A             |
| *Xylella fastidiosa*              | Xfa TrpC             | 15837975        |
| *Thermotoga maritima*             | Tma TrpC             | 15642913        |
| *Rhodobacter capsulatus*          | Rca TrpC             | N/A             |
| *Streptococcus mutans*            | Smu TrpC             | N/A             |
| *Aquifex aeolicus*                | Aae TrpC             | 15607040        |
| *Chlorobium tepidum*              | Cte TrpC             | N/A             |
| *Nostoc punctiforme*              | Npu TrpC             | N/A             |
| *Streptococcus pneumoniae*        | Spn TrpC             | 15901642        |
| *Anaabaena sp.*                   | Ana TrpC             | N/A             |
| *Clostridium acetobutylicum*       | Cac TrpC             | 15896407        |
| *Rhodopseudomonas palustris*       | Rpa TrpC             | N/A             |
| *Synechocystis sp.*               | Syn TrpC             | 16331130        |
| *Haemophilus influenzae*          | Hin TrpC             | 16273300        |
| *Salmonella typhimurium*          | Sty TrpC             | 16765069        |
| *Bacillus steathermobophilus*      | Bst TrpC             | N/A             |
| *Yersinia pestis*                 | Ype TrpC             | 16122433        |
| *Vibrio cholerae*                 | Vch TrpC             | 15641184        |
| *Pasteurella multocida*           | Pmu TrpC             | 15602445        |
| *Yersinia pseudotuberculosis*     | Yps TrpC             | N/A             |
| *Deinococcus radiodurans*         | Dra TrpC             | 15805163        |
| *Bacillus subtilis*               | Bsu TrpC             | 421536          |
| *Escherichia coli*                | Eco TrpC             | 16129223        |
| *Helicobacter pylori*             | Hpy TrpC             | 15645893        |
| *Staphylococcus aureus*           | Sau TrpC             | 15924361        |
| *Bacillus halodurans*             | Bha TrpC             | 15614225        |
| *Synechococcus sp.*               | Ssp. TrpC            | N/A             |
| *Prochlorococcus marinus*         | Pma TrpC             | N/A             |
| *Chlamydia trachomatis*           | Ctr TrpC             | 15605050        |
| *Chlamydia muridarum*             | Cmu TrpC             | 15835220        |
| *Corynebacterium diphtheriae*      | Cdi TrpC             | N/A             |
| *Methanococcus jannaschii*        | Mja TrpC             | 15668627        |
| *Pyrococcus furiosus*             | Pfu TrpC             | 18978079        |
| *Archaeoglobus fulgidus*          | Afu TrpC             | 11499194        |
| *Pyrococcus abyssii*              | Pab TrpC             | N/A             |
| *Methanobacterium thermoautotrophicum* | Mth TrpC | 136346 |
| *Methanococcus maripaludis*       | Mma TrpC             | N/A             |

### Table 2 (continued)

| Genes evaluated                  | Gene-product acronym | NCBI GI number* |
|-----------------------------------|----------------------|-----------------|
| Ferroplasma acidarmanus           | Fac TrpC             | N/A             |
| Saccharomyces cerevisiae           | Sce TrpC             | 6320210         |
| Arabidopsis thaliana               | Ath TrpC             | 5031254         |
| *trpEa*                           |                      |                 |
| *Salmonella typhimurium*          | Sty TrpEa            | 16765071        |
| *Chlamydia trachomatis D*         | Ctra TrpEa           | 15604890        |
| *Chlamydia psittaci*              | Cpsi TrpEa           | N/A             |
| Homologs of *E. coli* TyrP, Mtr and TnaB (Figure 7)* | | |
| *Chlamydia psittaci*              | Cpsi                | N/A             |
| *Chlamydia pneumoniae* CWL029     | Cpn-1               | 15618876        |
| *Chlamydia pneumoniae* CWL029     | Cpn-2               | 15618878        |
| *Chlamydia muridarum*             | Cmu-1               | 15834824        |
| *Chlamydia muridarum*             | Cmu-2               | 15834825        |
| *Chlamydia trachomatis D*         | Ctr-1               | 15605552        |
| *Chlamydia trachomatis D*         | Ctr-2               | 15605533        |
| *Haemophilus ducreyi*             | Hdu-1               | N/A             |
| *Haemophilus ducreyi*             | Hdu-2               | N/A             |
| *Haemophilus ducreyi*             | Hdu-3               | N/A             |
| *Nostoc punctiforme*              | Npu                 | N/A             |
| *Haemophilus influenzae*          | Hin                 | 16272242        |
| *Haemophilus influenzae*          | Hin-2               | 16272424        |
| *Haemophilus influenzae*          | Hin-3               | 16272472        |
| *Pasteurella multocida*           | Pmu-1               | 15602597        |
| *Pasteurella multocida*           | Pmu-2               | 15603057        |
| *Pasteurella multocida*           | Pmu-3               | 15602675        |
| *Pasteurella multocida*           | Pmu-4               | 15603284        |
| *Vibrio cholerae*                 | Vch-1               | 15601527        |
| *Vibrio cholerae*                 | Vch-2               | 15600930        |
| *Escherichia coli*                | TyrP                | 16129857        |
| *Escherichia coli*                | Mtr                 | 16131053        |
| *Escherichia coli*                | TnaB                | 16131577        |
| *Yersinia pestis*                 | Ype-1               | 16121500        |
| *Yersinia pestis*                 | Ype-2               | 16121568        |
| *Salmonella typhi*                | Sty-1               | 16760884        |
| *Salmonella typhi*                | Sty-2               | 16762044        |
| *Neisseria meningitidis*          | Nme                 | 15677855        |
| *Pseudomonas aeruginosa*          | Pae-1               | 15600627        |
| *Pseudomonas aeruginosa*          | Pae-2               | 15597112        |
| *Pseudomonas aeruginosa*          | Pae-3               | 15598961        |
| *Neisseria gonorrhoeae*           | Ngo                 | N/A             |
The chlamydiae are dependent on host cells for a variety of metabolites that are relevant to the host-parasite relationships of tryptophan metabolism. These include kynurenine, serine, ATP and tryptophan itself. Hence, the nature and variability for transport of these compounds should be of considerable interest.

Species of chlamydiae possess one (C. psittaci) or two (C. muridarum, C. trachomatis and C. pneumoniae) homologs of genes encoding the well characterized hydroxy/aromatic amino acid (HAAAP) permease family [48]. Figure 7 presents an unrooted radial tree that shows the chlamydial proteins to comprise a distinct cluster. E. coli Mtr (high-affinity tryptophan permease) and TnaB (low-affinity tryptophan permease) comprise one distinct group, and E. coli TyrP homologs make up another distinct group. The chlamydial sequences are approximately equidistant from the TyrP/Mtr-TnaB groupings. These chlamydial proteins might be broad-specificity transporters of tryptophan, tyrosine, phenylalanine and perhaps kynurenine as well.

When the Na⁺-coupled serine symporter SdaC from E. coli was used as a query against the chlamydial genomes, TyrP was the top hit (22% identity). This reflects the membership of SdaC proteins in the HAAAP family. An alternative query, the E. coli CycA serine/alanine/glycine transporter, yielded CT216 as the top hit (only 22% identity). E. coli possesses a Na⁺-coupled serine symporter, SttT, which is regulated by tryptophan [49]. Although this is but one of at least five different transporters for serine in E. coli, sttT encodes the sole serine/threonine transporter in Porphyromonas gingivalis [50]. Species of chlamydiae possess two paralogs of SttT, which were judged to be the most likely genes encoding serine transport. Perhaps one favors serine transport and the other threonine transport. Figure 8 shows an unrooted tree of SttT proteins.

### The tryptophan repressor

The presence of trpR implies that the tryptophan operon is under repression control by L-tryptophan, and some experimental evidence does indeed show derepression under conditions of tryptophan limitation [43]. Starvation for host-derived L-tryptophan, which is initiated by induction of indoleamine dioxygenase by IFN-γ, undoubtedly triggers derepression of the entire tryptophan operon, including the genes encoding PRPP synthase and kynureninase. Kynureninase from C. psittaci is a key linker between the anthranilate-utilizing TrpB enzyme that initiates tryptophan biosynthesis in the parasite and the host kynurenine foramidase that generates kynurenine. In effect a hybrid host-parasite cycle is generated in which a metabolic stream in

**Table 2 (continued)**

| Genes evaluated | Gene-product acronym | NCBI GI number |
|-----------------|----------------------|----------------|
| Homologs of E. coli SstT and Pgin SstT (Figure 8) | | |
| Chlamydia trachomatis (Group A) | Ctra | gill5605126 |
| Chlamydia muridarum (Group A) | Cmu | gill5835296 |
| Chlamydia pneumoniae (Group A) | Cpn | gill5618439 |
| Chlamydia trachomatis (Group B) | Ctra | gill5604951 |
| Chlamydia muridarum (Group B) | Cmu | gill5835119 |
| Chlamydia pneumoniae (Group B) | Cpn | gill5618209 |
| Porphyromonas gingivalis | Pgin | N/A |
| Corynebacterium diphtheriae | Cdpi | N/A |
| Clostridium difficile | Cdi | N/A |
| Treponema pallidum | Tpa | gill5639544 |
| Vibrio cholerae | Vch | gill5600807 |
| Pseudomonas aeruginosa | Pae | gill5597238 |
| Yersinia pestis | Ype | gill6120913 |
| Escherichia coli | Eco | gill6130984 |
| Yersinia pseudotuberculosis | Ype | N/A |
| Campylobacter jejuni | Cje | gill5792422 |
| Haemophilus influenzae | Hin | gill623445 |
| Pasteurella multocida | Pmu | gill5602756 |
| Neisseria meningitidis | Nme | gill5793312 |
| Neisseria gonorrhoeae | Ngo | N/A |
| Haemophilus ducreyi | Hdu | N/A |
| Enterococcus faecium | Efa | N/A |
| Streptococcus pyogenes | Spg | gill5674487 |
| Streptococcus pneumoniae | Spn | gill5903640 |
| Streptococcus equi | Seq | N/A |

*N/A applies to genes not yet included in the NCBI database. Includes in addition to identifiers of the four sequences shown in Figure 4, the sequence identifiers for the sequences used in the multiple alignment that supports the gaps and conserved residues indicated on line 1 of Figure 4. ‡See [30] for the sequence identifiers used in the multiple alignment which supports the gaps and conserved residues indicated on line 1 of Figure 5. §See [29] for the sequence identifiers used in the multiple alignment which supports the gaps and conserved residues indicated on line 1 of Figure 6.

in LifA integrity or copy number could easily explain variation in IFN-γ sensitivity and the nutritional requirement for L-tryptophan in vitro.

Except for C. psittaci, we may be seeing different strains in varied states of reductive evolution with respect to what remnants of genes for tryptophan biosynthesis remain. C. pneumoniae and C. trachomatis B lack genes encoding the entire tryptophan pathway. C. trachomatis D possesses trpC, trpEa and trpEb; C. muridarum possesses only trpC; C. trachomatis A and C possess trpEa and trpEb. The truncation of trpEa in C. trachomatis A and C, the likely pseudogene status of trpEa in serovar D, and the absence of trpEa altogether in serovar B indicates an active ongoing process of reductive evolution.
the host away from tryptophan is intercepted by a metabolic stream toward tryptophan in *C. psittaci*.

The thoroughly studied repressor protein that regulates tryptophan biosynthesis in *E. coli* is of limited phylogenetic distribution. In fact, *Xylella fastidiosa*, *C. trachomatis* and *C. psittaci* are the only organisms outside the enteric lineage known to possess *trpR*. The GC content of *trpR* was examined for evidence of possible horizontal transfer. Table 3 lists the GC content of *trpR* genes, compared to the GC content of the corresponding genomes. The *trpR* GC content of each organism corresponded relatively well to the genomic GC content, except for *X. fastidiosa* where *trpR* exhibited a low GC content, more similar to that of the chlamydiae or *H. influenzae*.

**Does *C. psittaci* have a regulon controlled by *trpR*?**

In *E. coli* the *trp* repressor binds upstream of the *trp* operon and upstream at the *mtr* transport gene in promoter regions where CTCG or CTAG are important for binding [51]. The *sstT* gene of *E. coli* is also subject to repression control by tryptophan and a CTCG upstream region has been proposed to be an additional target region for TrpR [49].

As *C. psittaci* has *trpR*, it seems quite possible that the *trp* operon, *sstT* (for serine transport), and *tyrP* (for tryptophan transport) are subject to repression control by TrpR [49].
transport) might comprise a regulon controlled by the trpR repressor. Indeed, CTAG and/or CTCG motifs were found upstream of all these genes in C. psittaci, but the presence of these regions did not exceed random probability sufficiently to justify any concrete assertions. The further use of a computational approach [52] to identify the transcription regulatory pattern was also not illuminating. As chlamydial TrpR proteins are the most divergent of TrpR proteins, the motif pattern for DNA binding may also be divergent.

**Conclusions**

Chlamydial parasites appear to respond to host mechanisms for restriction of tryptophan availability with a diversity of strategies, the exact nature of which we still know very little. One strategy utilized by C. muridarum employs a three-copy dose of lfpA, which could inhibit cytokine proliferation and decrease IFN-γ production by the host (although at least some IFN-γ has been shown to be produced in mice infected with C. muridarum [53]). Such a strategy would seem to be consistent with acute infections, which can be a successful mode of pathogenicity in some situations, such as high-density rodent populations. In the case of C. muridarum, the mechanism does not necessarily involve blocking the induction of indoleamine dioxygenase and thereby preventing depletion of host tryptophan, in view of some experimental work with the MoPn/mouse model system. The primary effect of the IFN-γ may not be to cause starvation for tryptophan as anti-chlamydial and anti-proliferative activities of murine IFN-γ in mouse cells was not reversible by tryptophan [54]. It has been concluded in other studies as well [55,56] that host-mediated tryptophan depletion is not an important factor in the MoPn/mouse model system. However, a conflicting conclusion was recently published by Perfettini et al. [57] that the inhibitory effect of IFN-γ in mouse cell cultures and genital tracts seems to be due in part to tryptophan depletion (because inhibition was partially reversed by tryptophan). It has been generally observed that in murine systems indoleamine dioxygenase has not been induced by IFN-γ under the same experimental conditions that readily induce synthesis of the enzyme in human systems. However, the potential to induce the dioxygenase in murine systems by IFN-γ exposure has been demonstrated when nitric oxide production is blocked [41]. Thus, it seems that the key difference between the mouse and human systems might lie in the details that dictate the balance between the cross-regulated pathways of tryptophan and arginine metabolism (see Figure 2). If so, in human systems the balance favors domination by the indoleamine dioxygenase route, whereas in murine systems the nitric oxide route is favored. Many individual factors could influence the balance, including differential sensitivities of NO synthase to inhibition by 3-hydroxyanthranilate or of indoleamine dioxygenase to inhibition by nitric oxide. In addition, unidentified cytokine-mediated mechanisms undoubtedly await elucidation.

In any event, for most chlamydiae the successful implementation of tryptophan depletion by the host is closely tied to chlamydial responses that result in a persistent metabolic state and chronic disease. It would appear that chlamydiae have learned to recognize and exploit tryptophan depletion as an environmental cue that initiates a distinct chain of remodeling biochemistry that promotes long-term viability in a latent state.

It is difficult to guess whether the ability of C. psittaci to scavenge kynurenine as a source of tryptophan is a recent innovation in this lineage, or whether it represents an ancient chlamydial strategy that has been abandoned by other chlamydiae. Perhaps the strategy is linked to the particular tissue tropism of C. psittaci. Because the presence of the tryptophan-pathway enzymes varies so markedly, even between closely related strains, one cannot be certain at this point that the tryptophan-recapture cycle is uniquely characteristic of C. psittaci. It cannot be ruled out that other strains of C. psittaci might lack the cycle, whereas some strains of C. trachomatis or C. pneumoniae not yet sequenced might possess it. Different overall host metabolism and different biochemical environments in various tissues undoubtedly influence the availability of kynurenine (as well as other metabolites such as ATP and serine). Hence, tissue tropism must be a crucial factor. It would be interesting to know whether the tryptophan-recapture cycle is capable of providing abundant tryptophan to the parasite, or whether it might be more subtly geared to provision of barely adequate tryptophan for parasites established in the chronic-infection mode.
Figure 7
Unrooted phylogenetic tree (radial view) of the TyrP family of transport proteins. A multiple alignment was obtained by input of the indicated sequences into the ClustalW program (version 1.4). Manual alignment adjustments were made with the assistance of the BioEdit multiple alignment tool of Hall [61]. The refined multiple alignment was used as input for generation of a phylogenetic tree using the program packages PHYLIP [62] and PHYLO_WIN [63]. The neighbor-joining and Fitch programs were used to obtain distance-based trees. The distance matrix was obtained using ProtDist with a Dayhoff PAM matrix. The Seqboot and Consense programs were then used to assess the statistical strength of the tree using bootstrap resampling. Neighbor-joining (shown) and Fitch trees yielded similar clusters and arrangement of taxa within them. Bootstrap values of 1,000 per 1,000 iterations (indicated with blue circles) supported the major nodes, one of which contains all of the chlamydial proteins. The experimentally documented E. coli proteins TyrP (tyrosine transport), Mtr (high-affinity tryptophan transport) and TraB (low-affinity tryptophan transport) are highlighted in yellow. See Table 2 for organism acronyms and gene identification numbers. In contrast to the two paralogs of tyrP present in C. pneumoniae CWLO29, as shown, some intra-species variation occurs in that C. pneumoniae J138 has only a single tyrP gene, and a small hypothetical gene is inserted between the two paralog tyrP genes of C. pneumoniae AR39.
Acknowledgements
Preliminary sequence data was obtained from the public website of The Institute for Genomic Research [58].

References
1. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, Olinger L, Grimwood J, Davis RW, Stephens RS: Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet 1999, 21:385-389.
2. Read TD, Brunham RC, Shen C, Gill SR, Heidelberg JF, White O, Hickey EK, Peterson J, Utterback T, Berry K, et al.: Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res 2000, 28:1397-1406.
3. Rockey DD, Lenart J, Stephens RS: Genome sequencing and our understanding of chlamydiae. Infect Immun 2000, 68:5473-5479.
4. Beatty WL, Morrison RP, Byrne GI: Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbial Rev 1994, 58:686-699.
5. Dreses-Werringloer U, Padubrin I, Jürgens-Saathoff B, Hudson AP, Zeidler H, Kohler L: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000, 44:3288-3297.
6. Jones ML, Gaston JH, Pearce JH: Induction of abnormal Chlamydia trachomatis by exposure to interferon-γ or amino acid deprivation and comparative antigenic analysis. Microb Pathogen 2001, 30:293-309.
7. Harper A, Pogson CI, Jones ML, Pearce JH: Chlamydial development is adversely affected by minor changes in amino acid...
supply, blood plasma amino acid levels, and glucose deprivation. Infect Immun 2000, 68:1457-1464.

8. Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat ACS. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992, 340:81-82.

9. Cotter TW, Ramsey KH, Miraanpuri GS, Poulson CE, Byrne: Dissemination of Chlamydia trachomatis chronic genital tract infection in gamma interferon gene knockout mice. Infect Immun 1997, 65:2415-2422.

10. Perry LL, Su H, Fellizzer K, Messer R, Hughes S, Whitmire W, Caldwell HD: Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-γ-mediated inhibition. J Immunol 1999, 162:5343-5348.

11. Igietseme JU, Ananaba GA, Candal DH, Lyn D, Black CM: Immune control of chlamydia growth in the human epithelial cell line RT4 involves multiple mechanisms that include nitric oxide induction, tryptophan catabolism and iron deprivation. Microbial Immunol 1998, 42:617-625.

12. Beaty WI, Belanger TA, Desai AA, Byrne GI: Tryptophan depletion as a mechanism of gamma-interferon-mediated chlamydial persistence. Infect Immun 1994, 62:3705-3711.

13. Byrne GI, Oeyahkin LD, Landry GJ: Induction of tryptophan catabolism by gamma-interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect Immun 1986, 53:347-351.

14. Byrne GI, Lehmann K, Kirschbaum JG, Bordens EC, Lee CM, Brown RR: Induction of tryptophan degradation in vitro and in vivo: a gamma interferon-stimulated activity. J Interferon Res 1986, 6:389-396.

15. Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991, 5:2516-2522.

16. Mehla S, Milliken RD, Romirez JA, Summersgitt JR: Inhibition of Chlamydia pneumoniae replication in HEP-2 cells by interferon-gamma: role of tryptophan catabolism. J Interferon Res 1998, 18:1326-1331.

17. Bertazzo A, Ragazzi E, Biasiol M, Cestra CVL, Allergeri G: Enzyme activities involved in tryptophan metabolism along the kynurenine pathway in rabbits. Biochim Biophys Acta 2001, 1527:167-175.

18. Haber R, Besette D, Hulihan-Giblin B, Durnan MJ, Goldman D: Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem 1991, 60:1159-1162.

19. Fleckner J, Rasmussen HH, Justesen J: Human interferon γ potently induces the synthesis of a 55-kDa protein (γ2) highly homologous to rabbit peptide chain release factor and bovine tryptophanyl-tRNA synthetase. Proc Natl Acad Sci USA 1992, 89:1120-1124.

20. Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984, 81:908-912.

21. Mackenzie CR, Langen R, Takikawa O, Daubener W: Inhibition of indoleamine 2,3-dioxygenase in human macrophages inhibits interferon-γ-induced bacteriostasis but does not abrogate toxoplasmas. Infect Immun 1999, 29:3254-3261.

22. Kudo, Y, Boyd CAR, Sargent IL, Redman CWG: Tryptophan degradation by human placental indoleamine 2,3-dioxygenase regulates lymphocyte proliferation. J Physiol 2001, 535:207-215.

23. Munn DH, Zou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by interferon-gamma. Science 1998, 281:191-193.

24. Widner B, Ledochowski M, Fuchs D: Interferon-gamma-induced tryptophan degradation: neurospsychiatric and immunological consequences. Curr Drug Metab 2000, 1:193-204.

25. Klapproth J-M, Scalesky IC, McNamara BP, Lai L-C, Malstrom C, Jondrup SP, Dengberg MS: A large toxin from pathogenic Escherichia coli strains that inhibits lymphocyte activation. Infect Immun 2000, 68:2148-2155.

26. Entrican G, Brown J, Graham S: Cytokines and the protective immune response to Chlamydia psittaci. Comp Immun Microbiol Infect Dis 1998, 21:155-162.

27. Sheney Y, Sarov I: Inhibition of growth of Chlamydia trachomatis by human gamma interferon. Infect Immun 1985, 48:592-596.

28. Brown J, Howie SEM, Entrican G: A role for tryptophan in immune control of chlamydial abortion in sheep. Vet Immunol Immunopath 2001, 82:107-119.

29. Belland RJ, Scidmore MA, Crane DD, Hogan DM, Whitmire W, McClarty G, Caldwell HD: Chlamydia trachomatis cytotoxicity associated with complete and partial cytotoxic genes. Proc Natl Acad Sci USA 2001, 98:11894-11899.

30. Xie G, Forst C, Bonner C, Jensen RA: Significance of two distinct types of tryptophan synthase beta chain in Bacteria, Archaea and higher plants. Genome Biol 2001, 3:research0004.1-0004.13.

31. Ilie-Lee ER, McClarty G: Regulation of carbon metabolism in Chlamydia trachomatis. Mol Microbiol 2000, 38:20-30.

32. Moroni F: Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999, 357:57-100.

33. MacKenzie CR, Willberg CB, Daubener W: Inhibition of group B streptococcal growth by IFN gamma-activated human glioblastoma cells. J Neuroimmunol 1998, 89:191-197.

34. Saito K, Crowley JS, Markey SP, Heyes MP: A mechanism for increased quinolinic acid formation following acute systemic tryptophan synthase. J Biol Chem 1993, 268:15496-15503.

35. Chiarugi A, Rapizzi E, Moroni F, Moroni F: The kynurenine metabolic pathway in the eye: studies on 3-hydroxykynurenine, a putative cataractogenic compound. FEBS Lett 1999, 453:197-203.

36. Bender DA: The kynurenine pathway of tryptophan metabolism. In Quinolinic Acid and the Kynurenines. Edited by Stone TW, New York: CRC Press; 1989: 3-38.

37. Toma S, Nakamura M, Tone S, Okuno E, Kido R, Breten J, Avanzi N, Czagel L, Speciale C, Postardini M et al.: Cloning and characterization of rat and human human kynureninase. FEBS Lett 1997, 408:5-10.

38. Koushik SV, Sundararaju B, McGraw RA, Phillips RS: Cloning, sequence, and expression of kynureninase from Pseudomonas fluorescens. Arch Biochem Biophys 1997, 344:301-308.

39. Sekkai D, Guittet O, Lemaire G, Tenu J-P, Lepoivre M: Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys 1998, 370:3711-3719.

40. Grant RS, Passey R, Matanovic G, Smythe G, Kapoor V: Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protection mechanism? Arch Biochem Biophys 1999, 372:1-7.

41. Thomas SR, Mohr D, Stocker R: Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. J Biol Chem 1994, 269:14457-14464.

42. Werner-Felmayer G, Werner ER, Fuchs D, Haussen A, Reibnegger G, Wachter H: Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta 1989, 1012:140-147.

43. Shaw AC, Christiansen G, Roepstorff P, Birkeland S: Genetic differences in the Chlamydia trachomatis tryptophan synthase alpha-subunit can explain variations in serovar pathogenicity. Microbes Infect 2000, 2:581-592.

44. Fehlner-Gardiner C, Rosschek C, Carlson JH, Hughes S, Belland RJ, Caldwell HD, McClarty G: Molecular basis defining human Chlamydia trachomatis tissue tropism: a possible role for tryptophanmediated inhibition and persistence of chlamydial growth in polarized and nonpolarized cells. Infect Immun 1999, 67:1666-1671.

45. Saier MH Jr: Families of transmembrane transporters selective for amino acids and their derivatives. Microbiology 2000, 146:1775-1795.

46. Ogawa W, Kim Y-M, Mizushima T, Tsuchiya T: Cloning and expression of the gene for the Na+-coupled serine transporter from Escherichia coli and characteristics of the transporter. J Bacteriol 1998, 180:6749-6752.
50. Dashper SG, Brownfield L, Slakeski N, Zilm PS, Rogers AH, Reynolds EC: Sodium ion-driven serine/threonine transport in Porphyromonas gingivalis. J Bacteriol 2001, 183:4142-4148.

51. Czernik PJ, Shin DS, Hurlbert BK: Functional selection and characterization of DNA binding sites for trp repressor of Escherichia coli. J Biol Chem 1994, 269:27869-27875.

52. Mironov AA, Koonin EV, Royberg MA, Gelfand MS: Computer analysis of transcription regulatory patterns in completely sequenced bacterial genomes. Nucleic Acids Res 1999, 27:2981-2989.

53. Beale AS: Does Chlamydia trachomatis MoPn enter microbologically-inapparent state during experimental infection of the mouse genital tract? Microb Pathogen 1997, 22:99-112.

54. de la Maza LM, Peterson EM, Gennie CW, Czarnecki CW: The anti-chlamydial and anti-proliferative activities of recombinant murine interferon-γ are not dependent on tryptophan concentrations. J Immunol 1985, 135:4198-4200.

55. Ramsey KH, Miranpuri GS, Poulsen CE, Marthakis NB, Braune LM, Byrne GI: Inducible nitric oxide synthase does not affect resolution of murine chlamydial genital tract infections or eradication of chlamydiae in primary murine cell culture. Infect Immun 1998, 66:835-838.

56. Ramsey KH, Miranpuri GS, Sigar IM, Ouellette S, Byrne GI: Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun 2001, 69:5131-5137.

57. Perfettini J-L, Darville T, Dauty-Yarsat A, Rank RG, Ojcius DM: Inhibition of apoptosis by gamma interferon in cells and mice infected with Chlamydia muridarum (the mouse pneumonia strain of Chlamydia trachomatis). Infect Immun 2002, 70:2559-2565.

58. The Institute of Genomic Research [http://www.tigr.org]

59. Ponting CP: Chlamydial homologues of the MACPF (MAC/perforin) domain. Curr Biol 1999, 9:R911-R913.

60. PDBsum [http://www.biochem.ucl.ac.uk/bsm/pdbsum/index.html]

61. Hall T: Biological Sequence Alignment Editor for Windows 95/98/NT, 5.09 ed. Raleigh, NC: North Carolina State University; 1997-2001. [http://www.mbio.ncsu.edu/BioEdit/bioedit.html]

62. Felsenstein J: PHYLIP - phylogeny inference package (version 3.2). Cladistics 1989, 5:164-166.

63. Galtier N, Douy M, Gautier C: SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny. Comput Appl Biosci 1996, 12:543-548.